Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01077453
Other study ID # NCI-2013-00757
Secondary ID NCI-2013-0075709
Status Completed
Phase Phase 1
First received February 26, 2010
Last updated October 17, 2014
Start date March 2010

Study information

Verified date October 2014
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This randomized phase I trial studies the side effects and the best dose of letrozole in preventing breast cancer in healthy postmenopausal women at high risk for breast cancer. Chemoprevention is the use of drugs to keep breast cancer from forming or coming back. The use of letrozole may keep cancer from forming in healthy postmenopausal women at high risk for breast cancer.


Description:

PRIMARY OBJECTIVES:

I. Compare the effect of lower and intermittent doses of letrozole to standard letrozole therapy on estrogen suppression in postmenopausal women at high risk for developing breast cancer.

SECONDARY OBJECTIVES:

I. Comparison of the effect of lower and intermittent doses of letrozole to standard therapy on signs and symptoms of estrogen deficiency, including menopausal symptoms, serum lipid profile, and serum marker of bone turnover.

II. Comparison of the effect of lower and intermittent doses of letrozole to standard therapy on nuclear chromatin abnormality of breast epithelial cells collected by random periareolar fine needle aspiration (RPFNA).

TERTIARY OBJECTIVES:

I. Determine the prevalence of breast cancer stem cells in the fine needle breast aspirates and explore the potential intervention effect on the prevalence of breast cancer stem cells.

OUTLINE: Patients are randomized to 1 of 4 treatment arms.

ARM I: Patients receive 2.5 mg of letrozole orally (PO) thrice weekly for 6 months.

ARM II: Patients receive 1.0 mg of letrozole PO thrice weekly for 6 months.

ARM III: Patients receive 0.25 mg of letrozole PO thrice weekly for 6 months.

ARM IV: Patients receive 2.5 mg of letrozole PO once daily for 6 months.

After completion of study treatment, patients are followed up at week 30.


Recruitment information / eligibility

Status Completed
Enrollment 112
Est. completion date
Est. primary completion date June 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 35 Years and older
Eligibility Inclusion Criteria:

- Healthy postmenopausal women at "high risk" for breast cancer will be eligible for the study; definition of menopause will be:

- Amenorrhea for at least 12 months, or

- History of hysterectomy and bilateral salpingo-oophorectomy, or

- At least 55 years of age with prior hysterectomy with or without oophorectomy, or

- Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of ovaries unknown with documented follicle-stimulating hormone level demonstrating elevation in postmenopausal range

- "High risk" for breast cancer will be defined as:

- Prior histologically confirmed lobular carcinoma in situ (LCIS) treated by local excision only, or

- At least 1.66% probability of invasive breast cancer within 5 years using the Breast Cancer Risk Assessment Tool

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; Karnofsky 80% or above

- Leukocytes >= 3,000/uL

- Absolute neutrophil count >= 1,500/uL

- Platelets >= 100,000/uL

- Total bilirubin =< 2.0 mg/dL

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.0 X institutional ULN

- Creatinine =< 1 X institutional ULN

- Recent mammogram negative for breast cancer, Breast Imaging-Reporting and Data System (BIRADS) score < 3 (within the last 12 months)

- Ability to understand and the willingness to sign a written informed consent document; only potential participants with the ability to understand and the willingness to sign a written document will be presented with an informed consenting document

Exclusion Criteria:

- Women diagnosed with osteoporosis (previously or on screening dual-energy X-ray absorptiometry [DEXA] for this study) and not on a stable dose of long or short-acting bisphosphonates therapy for at least 3 months will be excluded from the study; women diagnosed with osteoporosis and on raloxifene (Evista) therapy will be excluded from the study; use of calcium and/or vitamin D for osteoporosis prevention or treatment is allowed; women with osteopenia will be allowed to participate in this study

- Have had invasive cancer within the past five years except non-melanoma skin cancer

- Evidence of suspicious of malignant disease on bilateral mammogram within the past year unless ruled out by further evaluation

- History of prior invasive breast cancer or intraductal carcinoma in situ, or history of prior radiation therapy to the chest or breast

- Participants may not be receiving any other investigational agents; participants may not be concurrently enrolled in another breast cancer prevention intervention trial

- History of allergic reactions attributed to compounds of similar chemical or biologic composition to letrozole

- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

- Within 3 months since prior estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin inhibitors, or antiandrogens

- Within 3 months since prior tamoxifen, raloxifene, or other selective estrogen-receptor modulators

- Within 3 months since regular use (more than 2 times a week) of prior estrogenic supplements or herbal remedies

- History of bleeding or clotting disorder; current or recent (within 3 months) use of Coumadin, Plavix or other systemic anticoagulant other than aspirin is not permitted if subject chooses to participate in the optional RPFNA procedure; if a subject chooses not to participate in the RPFNA procedure, prior or current treatment with systemic anticoagulants is permitted

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Intervention

Drug:
letrozole
Given orally
Other:
quality-of-life assessment
Ancillary studies
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota
United States Arizona Cancer Center - Tucson Tucson Arizona
United States University of Arizona Health Sciences Center Tucson Arizona

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Prevalence of breast cancer stem cells by the proportion of aldehyde dehydrogenase positive cells, assessed by the Aldeflour assay Up to week 30 No
Other Relative expression of stem cell markers to housekeeping genes, assessed by quantitative real time polymerase chain reaction Up to week 30 No
Primary Percentage of serum estradiol suppression in postmenopausal women at high risk for breast cancer Three one-sided two-sample t-tests will be conducted on the ratios of the mean percentage of suppression simultaneously to test for non-inferiority. A multivariate t-distribution is used to derive the critical value and the power. Baseline to week 30 No
Secondary Change in serum estrone levels Three one-sided two-sample t-tests will be performed to evaluate the ratio of the mean changes (or percentage of changes) of each of the three intermittent dosing groups to that of the standard therapy control group simultaneously for each of the endpoints at an overall significance level of 5%. Baseline to week 30 No
Secondary Change in serum testosterone levels Three one-sided two-sample t-tests will be performed to evaluate the ratio of the mean changes (or percentage of changes) of each of the three intermittent dosing groups to that of the standard therapy control group simultaneously for each of the endpoints at an overall significance level of 5%. Baseline to week 30 No
Secondary Menopausal symptoms as assessed by quality of life measures, as assessed by Medical Outcomes Study 36-item Short Form Health Survey (SF-36) and Menopause Specific Quality of Life Questionnaire (MENQOL) Up to week 30 No
Secondary Nuclear chromatin abnormality as assessed by karyometry Up to week 30 No
See also
  Status Clinical Trial Phase
Completed NCT01950403 - Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers Phase 1
Terminated NCT01336387 - Dose-Finding of Retinoid 9cUAB30 in Healthy Volunteers Phase 1
Terminated NCT01561989 - Cholecalciferol and Flu Vaccine in Treating Healthy Participants N/A
Completed NCT01140646 - Evaluation of SAMe for Hot Flashes Phase 2
Completed NCT00892515 - Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer N/A
Completed NCT00365209 - Phase II A Trial of Curcumin Among Patients With Prevalent Subclinical Neoplastic Lesions (Aberrant Crypt Foci) Phase 2
Completed NCT00450957 - Lycopene in Healthy Male Participants Phase 1
Recruiting NCT04445532 - Hepatobiliary Tumors Tissue Samples Acquisition
Completed NCT02100254 - Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities N/A
Completed NCT02129517 - Web-Based Tailored Educational Program in Improving Nurse Communication With Patients About Clinical Trials N/A
Terminated NCT01755208 - Light-Scattering Spectroscopy for Detection of Breast Cancer N/A
Completed NCT00392652 - Diindolylmethane in Healthy Volunteers Phase 1
Completed NCT00499460 - Effects of Garlic Supplements on Opioids in Healthy Volunteers Phase 4
Completed NCT00478309 - Genetic Epidemiology Risk Assessment Program or Usual Care in Colorectal Cancer Screening for Healthy Participants N/A
Completed NCT01370889 - Resveratrol in Postmenopausal Women With High Body Mass Index Phase 1
Completed NCT00896207 - Studying Different Formulations of SR13668 in Healthy Volunteers Phase 1
Completed NCT00679094 - Bowman-Birk Inhibitor Concentrate in Healthy Men Phase 1
Terminated NCT02154984 - Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants N/A
Completed NCT00489372 - Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients Phase 1
Completed NCT00513916 - Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women Phase 3